Ubeslo (obicetrapib)

Where it stands

Ubeslo (obicetrapib), from A. Menarini International Licensing S.A., received a CHMP positive opinion on 2026-07-23 for the treatment of primary hypercholesterolaemia or mixed dyslipidaemia. The records show the product at 'Opinion' status in the EU, with no approval date recorded yet.

A CHMP opinion is a scientific recommendation to the European Commission and is not itself a marketing authorisation. The authorisation becomes legally effective only when the Commission adopts its decision. The records give an expected EC decision date of 2026-09-28, but this is an estimate (CHMP opinion plus 67 days, the standard Commission decision period) and not an official date.

The records also list Evlarco (obicetrapib) as the same substance in the EU, also at 'Opinion' status. The records do not explain how Ubeslo and Evlarco relate, for example whether they are separate marketing authorisations or different brand names. They also do not say which company holds Evlarco. That relationship should not be assumed.

Regulatory pathway and designations

No designations are recorded for Ubeslo. The records show no orphan, PRIME, or other special-status entries. They do not state the type of marketing authorisation (for example standard or conditional) or the assessment timetable.

In general EU procedure, a positive CHMP opinion is followed by Commission decision-making that typically takes about 67 days. This is the basis for the 2026-09-28 estimate. Once the decision is adopted, the authorisation applies across EU Member States. The records do not confirm any of these later steps for Ubeslo.

The indication in the records is broad: primary hypercholesterolaemia or mixed dyslipidaemia. The records do not include the exact wording of the approved indication, any conditions of use, or whether it is restricted to particular patient groups or combinations with other therapies.

Safety and pharmacovigilance

The records do not cover safety data, the risk management plan, contraindications, warnings, or post-authorisation commitments for Ubeslo. No conclusions about its safety profile can be drawn from the information provided.

In general, an EU authorisation is accompanied by a risk management plan and routine pharmacovigilance obligations for the marketing authorisation holder. Any product-specific measures would appear in the product information and CHMP assessment documents, which are not part of these records.

What to watch

The main milestone is the European Commission decision. The estimated date is 2026-09-28, but it is not official and the actual timing may differ. Watch for the approval date to be recorded and for the status to move from 'Opinion' to an authorised status.

Also watch how Evlarco progresses, since it is the same substance at the same 'Opinion' status. The records do not say whether the two products will receive decisions on the same timeline.

Once the final product information is published, check the exact indication wording, any conditions, and the safety sections. These details are not available in the current records.